Stay up-to-date in pulmonary and critical care. No spam.
Patients taking pramipexole for 6 months had a 14-point fall in their IRLS score, and 59% "responded" (had at least a 50% fall in their score). But time worked well, too: placebo patients had an 11-point decline in scores and 43% responded. So 1 in 6 responded to pramipexole, practically speaking (they don't say this, though). Augmentation also occurred more in the pramipexole group (9%), and rose with time on the drug, report Hogl et al. (n=331). Sleep Medicine 2011;12:351-360.